The KATP channel activator diazoxide ameliorates amyloid-β and Tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease

Dong Liu, Michael Pitta, Jong Hwan Lee, Balmiki Ray, Debomoy Lahiri, Katsutoshi Furukawa, Mohamed Mughal, Haiyang Jiang, Julissa Villarreal, Roy G. Cutler, Nigel H. Greig, Mark P. Mattson

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Compromised cellular energy metabolism, cerebral hypoperfusion, and neuronal calcium dysregulation are involved in the pathological process of Alzheimer's disease (AD). ATP-sensitive potassium (KATP) channels in plasma membrane and inner mitochondrial membrane play important roles in modulating neuronal excitability, cell survival, and cerebral vascular tone. To investigate the therapeutic potential of drugs that activate KATP channels in AD, we first characterized the effects of the KATP channel opener diazoxide on cultured neurons, and then determined its ability to modify the disease process in the 3xTgAD mouse model of AD. Plasma and mitochondrial membrane potentials, cell excitability, intracellular Ca2+ levels and bioenergetics were measured in cultured cerebral cortical neurons exposed to diazoxide. Diazoxide hyperpolarized neurons, reduced the frequency of action potentials, attenuated Ca2+ influx through NMDA receptor channels, and reduced oxidative stress. 3xTgAD mice treated with diazoxide for 8 months exhibited improved performance in a learning and memory test, reduced levels of anxiety, decreased accumulation of Aβ oligomers and hyperphosphorylated tau in the cortex and hippocampus, and increased cerebral blood flow. Our findings show that diazoxide can ameliorate molecular, cytopathological, and behavioral alterations in a mouse model of AD suggesting a therapeutic potential for drugs that activate KATP channels in the treatment of AD.

Original languageEnglish
Pages (from-to)443-457
Number of pages15
JournalJournal of Alzheimer's Disease
Volume22
Issue number2
DOIs
StatePublished - 2010

Fingerprint

Diazoxide
KATP Channels
Amyloid
Alzheimer Disease
Pathology
Neurons
Energy Metabolism
Cerebrovascular Circulation
Cell Membrane
Aptitude
Mitochondrial Membrane Potential
Mitochondrial Membranes
Pathologic Processes
N-Methyl-D-Aspartate Receptors
Pharmaceutical Preparations
Action Potentials
Blood Vessels
Hippocampus
Cell Survival
Oxidative Stress

Keywords

  • 3xTgAD
  • calcium
  • cerebral blood flow
  • diazoxide
  • excitotoxicity
  • hippocampus
  • hyperpolerization
  • KATP channels
  • learning and memory

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

The KATP channel activator diazoxide ameliorates amyloid-β and Tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. / Liu, Dong; Pitta, Michael; Lee, Jong Hwan; Ray, Balmiki; Lahiri, Debomoy; Furukawa, Katsutoshi; Mughal, Mohamed; Jiang, Haiyang; Villarreal, Julissa; Cutler, Roy G.; Greig, Nigel H.; Mattson, Mark P.

In: Journal of Alzheimer's Disease, Vol. 22, No. 2, 2010, p. 443-457.

Research output: Contribution to journalArticle

Liu, D, Pitta, M, Lee, JH, Ray, B, Lahiri, D, Furukawa, K, Mughal, M, Jiang, H, Villarreal, J, Cutler, RG, Greig, NH & Mattson, MP 2010, 'The KATP channel activator diazoxide ameliorates amyloid-β and Tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease', Journal of Alzheimer's Disease, vol. 22, no. 2, pp. 443-457. https://doi.org/10.3233/JAD-2010-101017
Liu, Dong ; Pitta, Michael ; Lee, Jong Hwan ; Ray, Balmiki ; Lahiri, Debomoy ; Furukawa, Katsutoshi ; Mughal, Mohamed ; Jiang, Haiyang ; Villarreal, Julissa ; Cutler, Roy G. ; Greig, Nigel H. ; Mattson, Mark P. / The KATP channel activator diazoxide ameliorates amyloid-β and Tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. In: Journal of Alzheimer's Disease. 2010 ; Vol. 22, No. 2. pp. 443-457.
@article{f41d73fb45bf4956b149a778078729a3,
title = "The KATP channel activator diazoxide ameliorates amyloid-β and Tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease",
abstract = "Compromised cellular energy metabolism, cerebral hypoperfusion, and neuronal calcium dysregulation are involved in the pathological process of Alzheimer's disease (AD). ATP-sensitive potassium (KATP) channels in plasma membrane and inner mitochondrial membrane play important roles in modulating neuronal excitability, cell survival, and cerebral vascular tone. To investigate the therapeutic potential of drugs that activate KATP channels in AD, we first characterized the effects of the KATP channel opener diazoxide on cultured neurons, and then determined its ability to modify the disease process in the 3xTgAD mouse model of AD. Plasma and mitochondrial membrane potentials, cell excitability, intracellular Ca2+ levels and bioenergetics were measured in cultured cerebral cortical neurons exposed to diazoxide. Diazoxide hyperpolarized neurons, reduced the frequency of action potentials, attenuated Ca2+ influx through NMDA receptor channels, and reduced oxidative stress. 3xTgAD mice treated with diazoxide for 8 months exhibited improved performance in a learning and memory test, reduced levels of anxiety, decreased accumulation of Aβ oligomers and hyperphosphorylated tau in the cortex and hippocampus, and increased cerebral blood flow. Our findings show that diazoxide can ameliorate molecular, cytopathological, and behavioral alterations in a mouse model of AD suggesting a therapeutic potential for drugs that activate KATP channels in the treatment of AD.",
keywords = "3xTgAD, calcium, cerebral blood flow, diazoxide, excitotoxicity, hippocampus, hyperpolerization, KATP channels, learning and memory",
author = "Dong Liu and Michael Pitta and Lee, {Jong Hwan} and Balmiki Ray and Debomoy Lahiri and Katsutoshi Furukawa and Mohamed Mughal and Haiyang Jiang and Julissa Villarreal and Cutler, {Roy G.} and Greig, {Nigel H.} and Mattson, {Mark P.}",
year = "2010",
doi = "10.3233/JAD-2010-101017",
language = "English",
volume = "22",
pages = "443--457",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - The KATP channel activator diazoxide ameliorates amyloid-β and Tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease

AU - Liu, Dong

AU - Pitta, Michael

AU - Lee, Jong Hwan

AU - Ray, Balmiki

AU - Lahiri, Debomoy

AU - Furukawa, Katsutoshi

AU - Mughal, Mohamed

AU - Jiang, Haiyang

AU - Villarreal, Julissa

AU - Cutler, Roy G.

AU - Greig, Nigel H.

AU - Mattson, Mark P.

PY - 2010

Y1 - 2010

N2 - Compromised cellular energy metabolism, cerebral hypoperfusion, and neuronal calcium dysregulation are involved in the pathological process of Alzheimer's disease (AD). ATP-sensitive potassium (KATP) channels in plasma membrane and inner mitochondrial membrane play important roles in modulating neuronal excitability, cell survival, and cerebral vascular tone. To investigate the therapeutic potential of drugs that activate KATP channels in AD, we first characterized the effects of the KATP channel opener diazoxide on cultured neurons, and then determined its ability to modify the disease process in the 3xTgAD mouse model of AD. Plasma and mitochondrial membrane potentials, cell excitability, intracellular Ca2+ levels and bioenergetics were measured in cultured cerebral cortical neurons exposed to diazoxide. Diazoxide hyperpolarized neurons, reduced the frequency of action potentials, attenuated Ca2+ influx through NMDA receptor channels, and reduced oxidative stress. 3xTgAD mice treated with diazoxide for 8 months exhibited improved performance in a learning and memory test, reduced levels of anxiety, decreased accumulation of Aβ oligomers and hyperphosphorylated tau in the cortex and hippocampus, and increased cerebral blood flow. Our findings show that diazoxide can ameliorate molecular, cytopathological, and behavioral alterations in a mouse model of AD suggesting a therapeutic potential for drugs that activate KATP channels in the treatment of AD.

AB - Compromised cellular energy metabolism, cerebral hypoperfusion, and neuronal calcium dysregulation are involved in the pathological process of Alzheimer's disease (AD). ATP-sensitive potassium (KATP) channels in plasma membrane and inner mitochondrial membrane play important roles in modulating neuronal excitability, cell survival, and cerebral vascular tone. To investigate the therapeutic potential of drugs that activate KATP channels in AD, we first characterized the effects of the KATP channel opener diazoxide on cultured neurons, and then determined its ability to modify the disease process in the 3xTgAD mouse model of AD. Plasma and mitochondrial membrane potentials, cell excitability, intracellular Ca2+ levels and bioenergetics were measured in cultured cerebral cortical neurons exposed to diazoxide. Diazoxide hyperpolarized neurons, reduced the frequency of action potentials, attenuated Ca2+ influx through NMDA receptor channels, and reduced oxidative stress. 3xTgAD mice treated with diazoxide for 8 months exhibited improved performance in a learning and memory test, reduced levels of anxiety, decreased accumulation of Aβ oligomers and hyperphosphorylated tau in the cortex and hippocampus, and increased cerebral blood flow. Our findings show that diazoxide can ameliorate molecular, cytopathological, and behavioral alterations in a mouse model of AD suggesting a therapeutic potential for drugs that activate KATP channels in the treatment of AD.

KW - 3xTgAD

KW - calcium

KW - cerebral blood flow

KW - diazoxide

KW - excitotoxicity

KW - hippocampus

KW - hyperpolerization

KW - KATP channels

KW - learning and memory

UR - http://www.scopus.com/inward/record.url?scp=78650844057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650844057&partnerID=8YFLogxK

U2 - 10.3233/JAD-2010-101017

DO - 10.3233/JAD-2010-101017

M3 - Article

C2 - 20847430

AN - SCOPUS:78650844057

VL - 22

SP - 443

EP - 457

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -